Similar articles

• Prevention of metabolic syndrome in serious mental illness.

  Ganguli R, Strassnig M. Ganguli R, et al. Psychiatr Clin North Am. 2011 Mar;34(1):109-25. doi: 10.1016/j.psc.2010.11.004. Psychiatr Clin North Am. 2011. PMID: 21333843
• [Reaction on 'Antipsychotics and metabolic abnormalities in children and adolescents; a review of the literature and some recommendations'].

  Cohen D, de Hert M. Cohen D, et al. Tijdschr Psychiatr. 2010;52(8):605-7; author reply 608. Tijdschr Psychiatr. 2010. PMID: 20698002 Dutch. No abstract available.
• Beyond the "hype" on the association between metabolic syndrome and atypical antipsychotics: the confounding effects of cohort, typical antipsychotics, severe mental illness, comedications, and comorbid substance use.

  de Leon J. de Leon J. J Clin Psychopharmacol. 2008 Apr;28(2):125-31. doi: 10.1097/JCP.0b013e318166f533. J Clin Psychopharmacol. 2008. PMID: 18344721 No abstract available.
• Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications.

  Hasnain M, Vieweg WV, Fredrickson SK, Beatty-Brooks M, Fernandez A, Pandurangi AK. Hasnain M, et al. Prim Care Diabetes. 2009 Feb;3(1):5-15. doi: 10.1016/j.pcd.2008.10.005. Epub 2008 Dec 10. Prim Care Diabetes. 2009. PMID: 19083283 Review.
• Rational antipsychotic choice: weighing the risk of tardive dyskinesia and metabolic syndrome.

  Stoklosa J, Öngür D. Stoklosa J, et al. Harv Rev Psychiatry. 2011 Sep-Oct;19(5):271-6. doi: 10.3109/10673229.2011.614100. Harv Rev Psychiatry. 2011. PMID: 21916828 Review. No abstract available.